Back to search

Article

Discovery of Semicarbazone and Thiosemicarbazone Analogs as Competitive SARS-CoV-2 Virus Main Protease (M <sup>pro</sup> ) Inhibitors

2026-03-12

Abstract excerpt

Despite the development of vaccines and antivirals, coronavirus disease 2019 (COVID-19) continues to affect populations worldwide. Given the high mutation rate of the SARS-CoV-2 virus and reports of drug resistance, there is a continued need for new therapeutic options. SARS-CoV-2 main protease (M pro ) is essential for viral replication and is a conserved target among coronaviruses. Most known M pro inhibitors...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a3c9b1da-6392-5260-9076-305d8c4eba19
DOI
10.64898/2026.03.11.711159
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Discovery of Semicarbazone and Thiosemicarbazone Analogs as Competitive SARS-CoV-2 Virus Main Protease (M <sup>pro</sup> ) InhibitorsDOI 10.64898/2026.03.11.711159
Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV‑2 Main ProteaseSemantic proximity
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacySemantic proximity
Structural basis for the inhibition of coronaviral main proteases by PF-00835231Semantic proximity
Structural basis for the inhibition of coronaviral main proteases by PF-00835231.Semantic proximity
High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent InhibitorSemantic proximity
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-M <sup>Pro</sup> inhibitors with potent in vivo efficacySemantic proximity
Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitorSemantic proximity
Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistanceSemantic proximity
Discovering potent inhibitors against the Mpro of the SARS-CoV-2. A Medicinal Chemistry approach.Semantic proximity
Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19Semantic proximity
ABBV-744 and Onalespid as Potential Inhibitors of SARS-CoV-2 main Protease Enzyme: A Promising Therapeutics in COVID-19?Semantic proximity
A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity
Select a neighboring publication to make it the new centre.